Erenumab for Idiosyncratic Facial Pain - Clinical Trial

What is the Purpose of this Study?

We are doing this study to test a drug, Erenumab, to see how well it works in lowering facial pain, pain medication use, and nose and sinus symptoms.

What is the Condition Being Studied?

Facial Pain

Who Can Participate in the Study?

-Adults 18-65 years old
-Have a sinus infection and/or facial pain or pressure.

Age Group

What is Involved?

If you choose to join this study, you will:
-Be randomized (like the flip of a coin) to Group1 or Group 2
--Group 1 will get the study drug (Erenumab) once per month for 8 months
--Group 2 will get a placebo (harmess saltwater) once per month for 8 months
-Complete a pain diary daily
-Complete several questionnaires

Study Details

Full Title
A Randomized, Double-Blinded, Single Site Study to Evaluate the Efficacy of Erenumab for Treatment of Idiosyncratic Facial Pain Mimicking Rhinosinusitis
Principal Investigator
Ear, Nose and Throat Doctor
Protocol Number
IRB: PRO00104284
NCT: NCT04249427
Phase IV
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center